Evidence map›Paper›PMID 34201089›Full record

ArticlePharmaceutics2021

Design and In Vitro Study of a Dual Drug-Loaded Delivery System Produced by Electrospinning for the Treatment of Acute Injuries of the Central Nervous System.

Luisa Stella Dolci, Rosaria Carmela Perone, Roberto Di Gesù, Mallesh Kurakula, Chiara Gualandi, Elisa Zironi, Teresa Gazzotti, Maria Teresa Tondo, Giampiero Pagliuca, Natalia Gostynska and 7 more

Abstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Luisa Stella DolciDepartment of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, Via S. Donato 15, 40127 Bologna, BO, Italy.
Rosaria Carmela PeroneDepartment of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, Via S. Donato 15, 40127 Bologna, BO, Italy.
Roberto Di GesùChemistry Department "G. Ciamician" and INST UdR of Bologna, Alma Mater Studiorum-University of Bologna, Via Selmi 2, 40126 Bologna, BO, Italy.ORCID 0000-0001-6196-643X
Mallesh KurakulaInterdepartmental Center for Health Sciences & Technologies (HST), CIRI-SDV, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.ORCID 0000-0002-8130-7068
Chiara GualandiChemistry Department "G. Ciamician" and INST UdR of Bologna, Alma Mater Studiorum-University of Bologna, Via Selmi 2, 40126 Bologna, BO, Italy.ORCID 0000-0002-2020-1892
Elisa ZironiDepartment of Veterinary Medical Sciences, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano Emilia, BO, Italy.ORCID 0000-0002-0934-5190
Teresa GazzottiInterdepartmental Center for Health Sciences & Technologies (HST), CIRI-SDV, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.ORCID 0000-0002-9938-7094
Maria Teresa TondoInterdepartmental Center for Health Sciences & Technologies (HST), CIRI-SDV, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.
Giampiero PagliucaInterdepartmental Center for Health Sciences & Technologies (HST), CIRI-SDV, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.ORCID 0000-0002-5882-7807
Natalia GostynskaInterdepartmental Center for Health Sciences & Technologies (HST), CIRI-SDV, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.
Vito Antonio BaldassarroInterdepartmental Center for Health Sciences & Technologies (HST), CIRI-SDV, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.ORCID 0000-0003-1020-4261
Maura CescattiIret Foundation, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.ORCID 0000-0003-3150-2639
Luciana GiardinoInterdepartmental Center for Health Sciences & Technologies (HST), CIRI-SDV, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.
Maria Letizia FocareteInterdepartmental Center for Health Sciences & Technologies (HST), CIRI-SDV, Alma Mater Studiorum-University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, BO, Italy.ORCID 0000-0002-0458-7836
Laura CalzàDepartment of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, Via S. Donato 15, 40127 Bologna, BO, Italy.
Nadia PasseriniDepartment of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, Via S. Donato 15, 40127 Bologna, BO, Italy.ORCID 0000-0002-3470-2700
Maria Laura BolognesiDepartment of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, Via S. Donato 15, 40127 Bologna, BO, Italy.ORCID 0000-0002-1289-5361

Funding

Emilia Romagna Region POR-FESR 2014-18, project "Step-by-Step
6 · The paper itself

Abstract

Vascular and traumatic injuries of the central nervous system are recognized as global health priorities. A polypharmacology approach that is able to simultaneously target several injury factors by the combination of agents having synergistic effects appears to be promising. Herein, we designed a polymeric delivery system loaded with two drugs, ibuprofen (Ibu) and thyroid hormone triiodothyronine (T3) to in vitro release the suitable amount of the anti-inflammation and the remyelination drug. As a production method, electrospinning technology was used. First, Ibu-loaded micro (diameter circa 0.95-1.20 µm) and nano (diameter circa 0.70 µm) fibers were produced using poly(l-lactide) PLLA and PLGA with different lactide/glycolide ratios (50:50, 75:25, and 85:15) to select the most suitable polymer and fiber diameter. Based on the in vitro release results and in-house knowledge, PLLA nanofibers (mean diameter = 580 ± 120 nm) loaded with both Ibu and T3 were then successfully produced by a co-axial electrospinning technique. The in vitro release studies demonstrated that the final Ibu/T3 PLLA system extended the release of both drugs for 14 days, providing the target sustained release. Finally, studies in cell cultures (RAW macrophages and neural stem cell-derived oligodendrocyte precursor cells-OPCs) demonstrated the anti-inflammatory and promyelinating efficacy of the dual drug-loaded delivery platform.

Indexed as

complex diseasesdual-drugibuprofenmulti-target drug designnanofibersSCIT3TBI

Identifiers

PMID34201089
PMCPMC8227370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.